Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The results of the annual check-up will be collected to evaluate the best urinary marker for fractional sodium excretion and salt status will be correlated to clinical outcome measures.
Patients with cystic fibrosis need extra salt as they have increased losses through sweat. Current advices are to follow and supplement if needed, however the way to follow salt depletion is unclear.
The best way is to calculate fractional salt excretion. This needs a simultaneous blood and urine sample for electrolytes and creatinin. Urinary surrogate markers have been validated on only 10 patients.
At the annual check-up patients with cystic fibrosis receive these measurements. The investigators will collect the measurements and calculate fractional excretion and the possible surrogate markers on urine. Further this will be correlated to nutritional and pulmonary status and patient subgroups at risk will be identified.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| fractional sodium excretion | Diagnostic Test | fractional sodium excretion will be compared to urinary sodium/creatinin, sodium/potassium ratio's and sodium concentration. | ||
| risk subgroups | Other | subgroup analysis will be performed to identify the patient groups at risk for sodium depletion |
| Measure | Description | Time Frame |
|---|---|---|
| fractional sodium excretion (percent) | = (serum creatinin X urinary Sodium)/(plasma sodiumX urinary creatinin) | 1 year |
| Urinary sodium/urinary creatinin (mmol/mmol) | calculated based on urinary results | 1 year |
| Fractional Chloride excretion (percent) | = (serum creatinin X urinary Chloride)/(plasma Chloride X urinary creatinin) | 1 year |
| Fractional Potassium excretion (%) | = (serum creatinin X urinary Potassium)/(plasma PotassiumX urinary creatinin) | 1 year |
| ratio urinary sodium/urinary potassium | = calculation of ration urinary sodium/potassium | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Body mass index | = Weight/Height X Height expressed as SD of the local population based on Flemish growth charts | 1 year |
| Forced expiratory volume in 1 second | measured with lungfunction testing expressed as % of normal for height |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
All cystic fibrosis patients for whom a complete analysis of both blood and urine is available at the time of their annual check-up
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Stephanie Van Biervliet, MD, PhD | Gent University hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Gent University Hospital | Ghent | 9000 | Belgium |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003550 | Cystic Fibrosis |
| ID | Term |
|---|---|
| D010182 | Pancreatic Diseases |
| D004066 | Digestive System Diseases |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 1 year |
| D030342 |
| Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D007232 | Infant, Newborn, Diseases |